Skip to main content

Security report for biogen.nl

Biogen Netherlands B.V. · Healthcare · Netherlands

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

78/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Netherlands B.V. operates as a leading global biotechnology company specializing in the development and commercialization of innovative medicines for complex neurological and rare diseases. The website reflects a mature enterprise with a clear focus on scientific innovation and patient impact, targeting healthcare professionals and patients in the Netherlands. The company is part of the larger Biogen Inc. group, founded in 1978, with a strong market position in neurology and related therapeutic areas. The website content is professionally presented, with comprehensive information about disease areas, products, corporate responsibility, and career opportunities. Technically, the website is built on Adobe Experience Manager, leveraging modern web technologies including Cookiebot for consent management, Google Analytics for traffic analysis, and Adobe Helix RUM for performance monitoring. The site is mobile-optimized and demonstrates good SEO and accessibility practices, though some accessibility features could be enhanced. Hosting appears to be on AWS infrastructure, indicated by load balancer cookies. Security posture is solid with HTTPS enforced, HttpOnly cookies, and a cookie consent mechanism. However, explicit security policies and incident response contacts are not published, representing an area for improvement. No vulnerabilities or suspicious content were detected. Privacy compliance is strong, with GDPR-aligned cookie management and privacy policy. Overall, the website is trustworthy, professional, and well-aligned with the company's business objectives. Strategic recommendations include publishing formal security and incident response policies, enhancing accessibility, and maintaining vigilance on third-party scripts and tracking technologies.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.nl

This scan found 19 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
95
Email security
60
DNS health
60
Network security
100
GDPR outside view
83
Average
78

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen Netherlands B.V. holds a strong position in the biotechnology healthcare sector, focusing on neurological and rare diseases. Their business model centers on research, development, and commercialization of specialty pharmaceuticals. The company benefits from the global Biogen brand and infrastructure, enabling extensive R&D pipelines and market reach. The website indicates a focus on patient and healthcare professional engagement, corporate responsibility, and talent acquisition. The presence of multiple country-specific Biogen domains suggests a broad international footprint. No direct revenue or financial data is disclosed, but the enterprise scale and global presence imply significant market influence. The company leverages partnerships and digital tools for marketing and analytics, supporting data-driven decision-making and compliance.

Security posture

The website demonstrates a mature security posture with HTTPS enforced and secure cookie attributes such as HttpOnly. The implementation of Cookiebot ensures user consent management aligned with GDPR. However, the absence of published security policies and incident response contacts limits transparency and preparedness perception. No security headers were explicitly detected in the provided data, suggesting room for improvement in defense-in-depth. The use of third-party scripts like Google Analytics and Cookiebot is managed with consent but requires ongoing monitoring for vulnerabilities. Overall, the site is secure for general use but could enhance trust by publishing formal security documentation and incident response procedures.

Recommendations

  1. Publish a formal security policy and make it accessible on the website.
  2. Provide clear incident response contact channels such as security@ or abuse@ emails.
  3. Implement and enforce security headers like Content-Security-Policy and X-Frame-Options.
  4. Regularly audit and update third-party scripts to mitigate vulnerabilities.
  5. Enhance accessibility features to improve compliance and user experience.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen Netherlands B.V.
Description
Biogen is een toonaangevend wereldwijd biotechnologiebedrijf dat voorop loopt in de wetenschap en innovaties ontwikkelt voor complexe en ernstige ziektes. Biogen ontwikkelt een pijplijn van potentiële medicijnen binnen neurologie, neuropsychiatrie, gespecialiseerde immunologie en zeldzame ziekten - om zo met onze wetenschap bij te dragen aan een gezondere, duurzamere en rechtvaardigere wereld.
Key services
development of medicines for multiple sclerosis, treatment for spinal muscular atrophy, co-development of treatments for Alzheimer's disease
Content quality
good
Branding
consistent

Technology

Stack
Adobe Helix RUM, Cookiebot, Google Tag Manager, jQuery 3.6.4, Video.js
Frameworks
Adobe Experience Manager (AEM)
Platforms
Adobe Experience Manager
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • HttpOnly cookies
  • Cookie consent mechanism implemented

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot
Marketing tools
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and well maintained.
  2. Comprehensive cookie consent and privacy mechanisms are implemented.
  3. No direct contact emails or phone numbers found; contact is via contact page form.
  4. Social media presence is linked to official Biogen accounts.
  5. No explicit security policy or incident response information published.
  6. Use of modern technologies and Adobe Experience Manager CMS.
  7. Good GDPR compliance indicators.
  8. No suspicious or malicious content detected.
Technical notes

Notes

The website is built on Adobe Experience Manager, a robust enterprise CMS platform, indicating a high level of technical maturity. It uses modern JavaScript libraries including jQuery 3.6.4 and Video.js for media content. Cookiebot is integrated for cookie consent management, and Google Tag Manager facilitates analytics and marketing tags. Hosting infrastructure appears to be AWS-based, inferred from load balancer cookies. Performance is moderate with asynchronous script loading and responsive design for mobile devices. SEO is supported by comprehensive meta tags and Open Graph data. Some scripts are loaded with type="text/plain" to control execution based on consent, reflecting privacy-aware implementation. Opportunities exist to optimize accessibility and security headers further to reduce technical debt and enhance resilience.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.nl. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.nl.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.